Award
National Cancer Institute 1R44CA295189-01A1
CTO1681 to prevent and mitigate cytokine release syndrome in multiple myeloma patients receiving CAR T-cell therapy
Recipient
CYTOAGENTS, INC.
Award Amount
$1,313,567.00
Ceiling
$1,313,567.00
Awarded
September 19, 2025
Identifier
1R44CA295189-01A1
Award to CytoAgents, Inc. for developing CTO1681 to prevent and treat cytokine release syndrome in multiple myeloma patients undergoing CAR T-cell therapy, including clinical trials to assess efficacy and safety.
Description
CytoAgents is developing CTO1681 for the prevention and treatment of cytokine release syndrome (CRS) associated with CAR T-cell therapy. The project includes a Phase 1b trial and plans for a Phase 2a trial in multiple myeloma patients. CTO1681 aims to reduce CRS severity, improve patient outcomes, and expand access to CAR T-cell therapy.